PolyActiva

Executive Summary

PolyActiva, an Australian clinical-stage biotechnology company, is pioneering sustained-release ocular implants using its proprietary PREZIA™ polymeric pro-drug platform. The technology enables precise, long-term drug delivery to the eye, addressing key limitations of conventional eye drops—such as poor patient compliance and fluctuating drug levels. The company’s lead programs target glaucoma, a chronic condition affecting over 80 million people worldwide, and rare pediatric retinal diseases where current treatment options are limited. PolyActiva’s biodegradable implants are designed to release therapeutic agents over months to years, potentially improving outcomes and reducing dosing burden. The platform’s versatility also supports a pipeline of candidates for other ophthalmic indications. With a strong intellectual property portfolio and a clear unmet need in ocular drug delivery, PolyActiva is well-positioned to advance into clinical trials. The company has demonstrated preclinical proof-of-concept and is progressing toward regulatory filings. Although still in the preclinical stage, its novel approach and focus on high-value markets suggest significant upside if clinical data are positive. Key near-term milestones include completion of IND-enabling studies and first-in-human trials, which could validate the platform and attract partnership interest. PolyActiva represents a compelling opportunity in the ophthalmic biotech space, with potential for transformative impact on patient care.

Upcoming Catalysts (preview)

• Q3 2026Completion of GLP Toxicology Studies for Lead Glaucoma Implant75% success
• Q4 2026Filing of Clinical Trial Application (CTA/IND) for Lead Candidate60% success
• Q2 2026Presentation of Preclinical Data at Major Ophthalmology Conference (e.g., ARVO)80% success